Antivirals Market to 2017 - Increased Uptake of High Priced Combination Drugs will Offset the Impact of Generics in the HIV Therapeutics Market by GBIResearch

VIEWS: 16 PAGES: 146

The report, which essentially provides insights into antivirals therapeutics sales forecasts until 2017. The report covers the key geographies of the US, the top five countries in the European region and Japan. Insights into the antiviral research and development pipeline and the potential future blockbusters by 2017 are included. The report provides an in-depth analysis of HIV, hepatitis, herpes and influenza therapeutic indications, and includes market forecasts and treatment usage patterns for these four therapeutic indications. The report also explores the competitive landscape, including benchmarking for the top companies in the market. Finally, a key trend analysis for mergers and acquisitions and licensing agreements involving antiviral therapies is also presented.

More Info
									   Antivirals Market to 2017 - Increased Uptake of High Priced
   Combination Drugs will Offset the Impact of Generics in the
                    HIV Therapeutics Market
 Reference Code: GBIHC163MR                                                                                                    Publication Date: April 2012


                                      The global antivirals market has shown moderate growth in the pharmaceutical market and is
                                      expected to grow further due to the increase in the diseased population, increase in disease
                                      awareness, and the launch of new drugs with better levels of efficacy. Late stage pipeline drugs
                                      Rilpivirine, Vicriviroc, Elvitegravir, Inavir and Rapiacta are expected to positively impact the market.
                                      The overall antiviral market is driven by Human Immunodeficiency Virus/Acquired Immune
                                      Deficiency Syndrome (HIV/AIDS) therapeutic sales which accounted for 61% of the market 2010.
                                      The Research and Development (R&D) pipeline appears moderately strong with 483 molecules,
                                      33% of which are in Phase II.
                                      High Priced Combination Drugs in the HIV Therapeutics Market and Launch of New Drugs
                                      will Drive Future Market Growth

                                       Antivirals Market, Global, Revenue ($bn), 2002-2017
  Antiviral therapeutics
  market is dominated by
                                                                35
  HIV/AIDS therapeutics
  sales which contributed
  61% of the total antiviral                                    30
                                                                                                      CAGR (2010-2017): 4.5%
  therapeutic market

                                                                25
                                               Revenues ($bn)




                                                                20   CAGR (2002-2010): 9.9%




                                                                15



                                                                10



                                                                 5



                                                                 0
                                                                      2002                           2010                             2017


                                       Source: GBI Research, Company Websites, Internal Forecasting Model, AVERT, CDC, WHO, UNICEF, UWEC, UNAIDS




                                      GBI Research estimates that overall antivirals market was worth $22.1 billion in 2010 and is
                                      expected to reach $30.1 billion by 2017 at a Compound Annual Growth Rate (CAGR) of 4.5%. In
                                      2002, the annual cost of treatment for HIV/AIDS was $9,971. It increased at a substantial CAGR of
                                      3.2% to $12,829 in 2010, driven by the launch of new combination therapies such as the multi-
                                      class combination drug Atripla. On the other hand, the expiry of key drugs such as Sustiva
                                      (efavirenz) in 2012 will cause a dip in the average cost of treatment from 2012, although the launch
                                      of combination drugs will offset the impact of generics. These drugs, although higher in price, have
                                      shown better results and are particularly effective for those who have developed a resistance to
                                      other HIV/AIDS drugs. Gilead filed a New Drug Application (NDA) for Quad, a combination of
                                      Gilead’s pipeline candidate Elvitegravir, Cobicistat and its currently marketed HIV drug Truvada.
                                      The launch of new antivirals such as Rilpivirine, Vicriviroc, Elvitegravir, Inavir and Rapiacta will
                                      further boost the growth of the antivirals market in the forecast period.



Antivirals Market to 2017 - Increased Uptake of High Priced                                                            GBIHC163MR /Published APR 2012
Combination Drugs will Offset the Impact of Generics in the HIV                                                                                      Page 1
Therapeutics Market                                                               © GBI Research. This report is a licensed product and is not to be copied,
                                                                                                                  reproduced, shared or resold in any form
                                      The HIV/AIDS Therapeutics Market will be Moderately Driven by Decreased Mortality and
                                      Increased Usage but will be Impacted by Patent Expiries

                                       HIV/AIDS Therapeutics Market, Global, Revenue ($m), 2002-2017

                                                              16,000
                                                                                                            CAGR (2010-2017): 1.4%


                                                              14,000



                                                              12,000


                                                                       CAGR (2002-2010): 10.9%
                                              Revenues ($m)   10,000



                                                               8,000



                                                               6,000



                                                               4,000



                                                               2,000



                                                                  0
                                                                              2002                          2010                         2017


                                       Source: GBI Research, Company Websites, Internal Forecasting Model, AVERT, CDC, WHO, UNICEF, UWEC, UNAIDS




                                      The HIV/AIDS therapeutics market is a growing market with the US dominating in terms of revenue.
                                      The market is driven by an increase in treatment seeking rates as well as the introduction of new
                                      drugs such as Atripla, a form of Highly Active Anti-Retroviral Therapy (HAART). The market is
                                      expected to grow at a slower rate in the forecast period, primarily due to the patent expiries of
                                      major drugs such as Sustiva and Combivir in 2012. Other drugs such as Epivir, Epzicom, Trizivir,
                                      Ziagen, Invirase and Lexiva went off patent in 2009 and 2010, although the impact will be partially
                                      offset by the increased use of new drugs which are more effective at tackling disease progression.
                                      The sale of new drugs such as Atripla has increased at a CAGR of 136% over the last three years,
                                      and the number of people receiving treatment for HIV/AIDS has been increasing at a CAGR of
                                      3.4% since 2010. In addition, the average Annual Cost of Therapy (ACT) for Anti-Retroviral
                                      Therapy (ART) is forecast to increase until 2013, after which patent expiries will result in a decline
                                      in price. However, the market revenue is expected to increase gradually towards the end of the
                                      forecast period due to increased usage of new drugs. Additionally, late stage pipeline drugs
                                      Edurant and Vicriviroc are expected to enter the market during the forecast period and act as a
                                      driver for growth.
                                      The Global Hepatitis Therapeutic Market is Forecast to Show High Growth
                                      The global hepatitis therapeutics market is expected to reach approximately $6.6 billion by 2017,
                                      growing at a CAGR of 9.8% from 2010. The hepatitis C market will grow at a high rate, while the
                                      hepatitis B market will witness low growth. The target patient base is newly infected or diagnosed
                                      hepatitis patients, non-responders and patients who have discontinued treatment. Thus, there is
                                      huge unmet need in the market. The high cost of therapy has also been a major cause of concern
                                      for patients. The current hepatitis C pipeline does however offer some promising novel products,
                                      and as a result the global hepatitis market is expected to show high growth in the future.




Antivirals Market to 2017 - Increased Uptake of High Priced                                                                 GBIHC163MR /Published APR 2012
Combination Drugs will Offset the Impact of Generics in the HIV                                                                                           Page 2
Therapeutics Market                                                                    © GBI Research. This report is a licensed product and is not to be copied,
                                                                                                                       reproduced, shared or resold in any form
                                       Hepatitis Therapeutics Market, Global, Revenue ($m), 2002-2017

                                                                 7,000



                                                                 6,000

                                                                                                         CAGR (2010-2017): 9.8%


                                                                 5,000




                                                 Revenues ($m)
                                                                 4,000

                                                                         CAGR (2002-2010): 3.1%

                                                                 3,000



                                                                 2,000



                                                                 1,000



                                                                    0
                                                                              2002                         2010                        2017


                                       Source: GBI Research, Annual Reports




                                      The Herpes Therapeutics Market has Low Unmet Need and a Weak Pipeline
                                      The pipeline portfolio for herpes simplex and Herpes Zoster (HZ) is weak, with 26 molecules in
                                      R&D and seven in Phase III. Five molecules are first-in-class. Patients treated with current
Zovirax, Famvir, Zostavax             therapies commonly experience headaches, nausea, dizziness and abdominal pain, thus the high
and Valtrex contribute for            demand for safer drugs.
more than $1.2 billion of
global herpes therapeutics            The herpes therapeutics market is strong in terms of antivirals such as Zovirax (acyclovir), Famvir
market.                               (famciclovir), Zostavax (HZ vaccine) and Valtrex (valacyclovir). These drugs account for more than
                                      $1.2 billion of the global herpes therapeutics market. Low cost generics account for a large sector
                                      of the market, thus resulting in the need for first-in-class drugs in order to boost growth.
                                      The herpes therapeutics market is expected to grow due to increasing awareness of the disease
                                      and the resultant increasing treatment rates. The number of prescribed patients will increase during
                                      the forecast period at a CAGR of 7.1%, thus increasing market revenue. Any negative impact from
                                      weak pipeline molecules will be countered by a growing prescription population.
                                      Launch of New Drugs with Better Efficacy will be a Key Driver of the Influenza Market
                                      The launch of new drugs with better efficacy will drive the market for influenza therapeutics. Tamiflu
                                      (oseltamivir phosphate) and Relenza (zanamivir) are currently the only antiviral drugs approved by
                                      the Food and Drug Administration (FDA) for the treatment of acute uncomplicated illness due to
                                      influenza A and B that are also approved for preventive use. Two older drugs, amantadine and
                                      rimantadine are also approved for the treatment and prevention of influenza A, although many
                                      strains of influenza have now become resistant to them. As a result, the Centers for Disease
                                      Control and Prevention (CDC) currently recommend their use only where specific virus strains are
                                      suspected. Antiviral drugs Inavir and Rapiacta were launched in Japan in 2010, and clinical studies
                                      have shown that they performed with better efficacy than major antiviral drug Tamiflu. They are
                                      expected to receive FDA approval as a result. Recent reports of Tamiflu-resistant viral strains will
                                      aid the growth of the influenza therapeutics market.




Antivirals Market to 2017 - Increased Uptake of High Priced                                                                 GBIHC163MR /Published APR 2012
Combination Drugs will Offset the Impact of Generics in the HIV                                                                                           Page 3
Therapeutics Market                                                                    © GBI Research. This report is a licensed product and is not to be copied,
                                                                                                                       reproduced, shared or resold in any form
                                      1         Table of Contents
                                      1   Table of Contents ........................................................................................................................ 4
                                          1.1    List of Tables..................................................................................................................... 7
                                          1.2    List of Figures ................................................................................................................... 9
                                      2   Antivirals Market to 2017 - Introduction ..................................................................................... 11
                                          2.1    Introduction ..................................................................................................................... 11
                                          2.2    GBI Research Report Guidance ..................................................................................... 11
                                      3   Antivirals Market to 2017 - Market Overview ............................................................................. 12
                                          3.1    Market Forecasts ............................................................................................................ 12
                                             3.1.1    Revenue .................................................................................................................. 12
                                             3.1.2    Global Branded vs Generic Market Share ............................................................... 14
                                             3.1.3    Annual Cost of Therapy ........................................................................................... 15
                                             3.1.4    Treatment Usage Patterns ...................................................................................... 16
                                          3.2    Drivers and Restraints for the Global Antivirals Therapeutics Market ............................. 18
                                             3.2.1    Market Drivers ......................................................................................................... 18
                                             3.2.2    Market Restraints .................................................................................................... 19
                                      4   Antivirals Market to 2017 - Geographical Landscape ................................................................ 20
                                          4.1    Revenue Analysis by Geography .................................................................................... 20
                                          4.2    The US ............................................................................................................................ 22
                                             4.2.1    Revenue .................................................................................................................. 22
                                             4.2.2    Annual Cost of Therapy ........................................................................................... 23
                                             4.2.3    Treatment Usage Patterns ...................................................................................... 24
                                          4.3    Top Five Countries of Europe ......................................................................................... 26
                                             4.3.1    Revenue .................................................................................................................. 26
                                             4.3.2    Annual Cost of Therapy ........................................................................................... 27
                                             4.3.3    Treatment Usage Patterns ...................................................................................... 28
                                          4.4    Japan .............................................................................................................................. 30
                                             4.4.1    Revenue .................................................................................................................. 30
                                             4.4.2    Annual Cost of Therapy ........................................................................................... 31
                                             4.4.3    Treatment Usage Patterns ...................................................................................... 32
                                      5   Antivirals Market to 2017 - Therapeutic Landscape................................................................... 34
                                          5.1    HIV/AIDS Therapeutics Market Forecasts ...................................................................... 34
                                             5.1.1    Introduction .............................................................................................................. 34
                                             5.1.2    Revenue .................................................................................................................. 36
                                             5.1.3    Branded vs Generic Market Share .......................................................................... 38
                                             5.1.4    Revenue Analysis by Country.................................................................................. 39
                                             5.1.5    Annual Cost of Therapy ........................................................................................... 41
                                             5.1.6    Treatment Usage Patterns ...................................................................................... 42
                                          5.2    Drivers and Restraints for the Global HIV/AIDS Therapeutics Market ............................ 48
                                             5.2.1    Market Drivers ......................................................................................................... 48
                                             5.2.2    Market Restraints .................................................................................................... 50
                                          5.3    Hepatitis Therapeutics Market Forecasts ........................................................................ 52
                                             5.3.1    Introduction .............................................................................................................. 52
                                             5.3.2    Revenue .................................................................................................................. 55
                                             5.3.3    Branded vs Generic Market Share .......................................................................... 57
                                             5.3.4    Revenue Analysis by Country.................................................................................. 58
                                             5.3.5    Annual Cost of Therapy ........................................................................................... 60
                                             5.3.6    Treatment Usage Patterns ...................................................................................... 61
                                          5.4    Drivers and Restraints for the Global Hepatitis Therapeutics Market.............................. 63
                                             5.4.1    Market Drivers ......................................................................................................... 63
                                             5.4.2    Market Restraints .................................................................................................... 64
                                          5.5    Herpes Therapeutics Market Forecasts .......................................................................... 64
                                             5.5.1    Introduction .............................................................................................................. 64
                                             5.5.2    Revenue .................................................................................................................. 67


Antivirals Market to 2017 - Increased Uptake of High Priced                                                                GBIHC163MR /Published APR 2012
Combination Drugs will Offset the Impact of Generics in the HIV                                                                                          Page 4
Therapeutics Market                                                                   © GBI Research. This report is a licensed product and is not to be copied,
                                                                                                                      reproduced, shared or resold in any form
                                           5.5.3    Branded vs Generic Market Share .......................................................................... 68
                                           5.5.4    Revenue Analysis by Country.................................................................................. 69
                                           5.5.5    Annual Cost of Therapy ........................................................................................... 71
                                           5.5.6    Treatment Usage Pattern ........................................................................................ 72
                                        5.6    Drivers and Restraints for the Global Herpes Therapeutics Market ................................ 73
                                           5.6.1    Market Drivers ......................................................................................................... 73
                                           5.6.2    Market Restraints .................................................................................................... 74
                                        5.7    Influenza Therapeutics Market Forecasts ....................................................................... 75
                                           5.7.1    Introduction .............................................................................................................. 75
                                           5.7.2    Revenue .................................................................................................................. 77
                                           5.7.3    Branded vs Generic Market Share .......................................................................... 78
                                           5.7.4    Revenue Analysis by Country.................................................................................. 79
                                           5.7.5    Annual Cost of Therapy ........................................................................................... 80
                                           5.7.6    Treatment Usage Patterns ...................................................................................... 81
                                        5.8    Drivers and Restraints for the Global Influenza Therapeutics Market ............................. 83
                                           5.8.1    Market Drivers ......................................................................................................... 83
                                           5.8.2    Market Restraints .................................................................................................... 83
                                      6 Antivirals Market to 2017 - Pipeline Analysis ............................................................................. 84
                                        6.1    R&D Pipeline by Phase................................................................................................... 84
                                        6.2    R&D Pipeline by Indication.............................................................................................. 85
                                        6.3    R&D Pipeline - HIV/AIDS ................................................................................................ 86
                                           6.3.1    Overview ................................................................................................................. 86
                                           6.3.2    Pipeline by Clinical Phase of Development ............................................................. 87
                                        6.4    Promising Molecules under Development - HIV/AIDS .................................................... 92
                                           6.4.1    Quad ........................................................................................................................ 92
                                           6.4.2    Elvitegravir ............................................................................................................... 92
                                           6.4.3    GSK1349572 ........................................................................................................... 93
                                        6.5    R&D Pipeline - Hepatitis ................................................................................................. 94
                                           6.5.1    Overview ................................................................................................................. 94
                                           6.5.2    R&D Pipeline by Indications .................................................................................... 95
                                        6.6    Promising Molecules under Development - Vaccines for Hepatitis B............................ 104
                                           6.6.1    Heplisav ................................................................................................................. 104
                                           6.6.2    Spi-VEC ................................................................................................................. 105
                                        6.7    Promising Molecules under Development - Therapeutics for Hepatitis B ..................... 105
                                           6.7.1    Entecavir plus Adefovir Combination Therapy ....................................................... 105
                                           6.7.2    Tenofovir plus Emtricitabine Combination Therapy ............................................... 106
                                           6.7.3    Pegylated Interferon Alfa-2a + Adefovir ................................................................. 106
                                        6.8    Promising Molecules under Development - Therapeutics for Hepatitis C ..................... 107
                                           6.8.1    Zalbin (albinterferon alfa-2b, Joulferon) ................................................................. 107
                                           6.8.2    RG 7128 ................................................................................................................ 108
                                        6.9    R&D Pipeline - Herpes .................................................................................................. 109
                                           6.9.1    Overview ............................................................................................................... 109
                                           6.9.2    R&D Pipeline by Indication .................................................................................... 110
                                           6.9.3    Herpes Simplex - Pipeline by Clinical Phase of Development ............................... 110
                                           6.9.4    Herpes Zoster - Pipeline by Clinical Phase of Development ................................. 112
                                        6.10 Promising Molecules under Development - Herpes ...................................................... 113
                                           6.10.1 BA-021 .................................................................................................................. 113
                                           6.10.2 NB-001 .................................................................................................................. 113
                                           6.10.3 ARYS-01 ............................................................................................................... 114
                                           6.10.4 GSK 1437173A...................................................................................................... 115
                                           6.10.5 V212 ...................................................................................................................... 115
                                        6.11 R&D Pipeline - Influenza ............................................................................................... 116
                                           6.11.1 Overview ............................................................................................................... 116
                                           6.11.2 Pipeline by Clinical Phase of Development ........................................................... 117
                                        6.12 Promising Molecules under Development - Influenza ................................................... 120

Antivirals Market to 2017 - Increased Uptake of High Priced                                                               GBIHC163MR /Published APR 2012
Combination Drugs will Offset the Impact of Generics in the HIV                                                                                         Page 5
Therapeutics Market                                                                  © GBI Research. This report is a licensed product and is not to be copied,
                                                                                                                     reproduced, shared or resold in any form
                                           6.12.1 S-021812 ............................................................................................................... 120
                                           6.12.2 CS-8958 ................................................................................................................ 121
                                           6.12.3 T-705 ..................................................................................................................... 121
                                      7 Antivirals Market to 2017: Competitive Landscape .................................................................. 122
                                        7.1    Profiles of Major Companies ......................................................................................... 122
                                           7.1.1    GlaxoSmithKline (GSK) ......................................................................................... 122
                                           7.1.2    Merck ..................................................................................................................... 123
                                           7.1.3    F. Hoffmann-La Roche Ltd. ................................................................................... 124
                                           7.1.4    Gilead Sciences, Inc .............................................................................................. 125
                                           7.1.5    Bristol-Myers Squibb (BMS) .................................................................................. 126
                                      8 Antivirals Market to 2017 - Strategic Consolidations ............................................................... 127
                                        8.1    Mergers and Acquisitions .............................................................................................. 127
                                           8.1.1    Segmentation by Indication ................................................................................... 127
                                           8.1.2    Segmentation by Geography ................................................................................. 128
                                           8.1.3    Segmentation by Deal Value ................................................................................. 129
                                           8.1.4    Major Mergers and Acquisitions Deals .................................................................. 130
                                        8.2    Licensing Deals............................................................................................................. 132
                                           8.2.1    Segmentation by Indication ................................................................................... 132
                                           8.2.2    Segmentation by Geography ................................................................................. 133
                                           8.2.3    Segmentation by Deal Value ................................................................................. 134
                                           8.2.4    Major Licensing Deals ........................................................................................... 135
                                      9 Antivirals Market to 2017 - Appendix ....................................................................................... 139
                                        9.1    Market Definitions ......................................................................................................... 139
                                        9.2    Abbreviations ................................................................................................................ 139
                                        9.3    Research Methodology ................................................................................................. 141
                                           9.3.1    Coverage ............................................................................................................... 141
                                           9.3.2    Secondary Research ............................................................................................. 141
                                           9.3.3    Primary Research .................................................................................................. 141
                                        9.4    Research Methodology ................................................................................................. 142
                                           9.4.1    Therapeutic Landscape ......................................................................................... 142
                                           9.4.2    Geographical Landscape....................................................................................... 145
                                           9.4.3    Pipeline Analysis ................................................................................................... 145
                                           9.4.4    Competitive Landscape ......................................................................................... 145
                                        9.5    Expert Panel Validation................................................................................................. 145
                                        9.6    Contact Us .................................................................................................................... 145
                                        9.7    Disclaimer ..................................................................................................................... 145
                                        9.8    Sources ......................................................................................................................... 146




Antivirals Market to 2017 - Increased Uptake of High Priced                                                               GBIHC163MR /Published APR 2012
Combination Drugs will Offset the Impact of Generics in the HIV                                                                                         Page 6
Therapeutics Market                                                                  © GBI Research. This report is a licensed product and is not to be copied,
                                                                                                                     reproduced, shared or resold in any form
                                      1.1       List of Tables
                                      Table 1:    Antivirals Market, Global, Revenue ($bn), 2002-2010.................................................... 12
                                      Table 2:    Antivirals Market, Global, Revenue Forecasts ($bn), 2010-2017 ................................... 12
                                      Table 3:    Antivirals Market, Global, Market Share by Indication, (%), 2010 .................................. 13
                                      Table 4:    Antivirals Market, Global, Annual Cost of Therapy ($), 2002-2010 ................................ 15
                                      Table 5:    Antivirals Market, Global, Annual Cost of Therapy ($), 2010-2017 ................................ 15
                                      Table 6:    Antivirals Market, Global, Treatment Usage Patterns (Millions), 2002-2010 .................. 16
                                      Table 7:    Antivirals Market, Global, Treatment Usage Patterns (Millions), 2010-2017 .................. 17
                                      Table 8:    Antivirals Market, Global, Revenue by Country ($m), 2002-2010 .................................. 20
                                      Table 9:    Antivirals Market, Global, Revenue Forecasts by Country ($m), 2010-2017.................. 21
                                      Table 10:   Antivirals Market, The US, Revenue ($m), 2002-2010 ................................................... 22
                                      Table 11:   Antivirals Market, The US, Revenue Forecasts ($m), 2010-2017 .................................. 22
                                      Table 12:   Antivirals Market, The US, Annual Cost of Therapy ($), 2002-2010............................... 23
                                      Table 13:   Antivirals Market, The US, Annual Cost of Therapy ($), 2010-2017............................... 23
                                      Table 14:   Antivirals Market, The US, Treatment Usage Patterns (Millions), 2002-2010 ................ 24
                                      Table 15:   Antivirals Market, The US, Treatment Usage Patterns (Millions), 2010-2017 ................ 25
                                      Table 16:   Antivirals Market, Top Five Countries of Europe, Revenue ($m), 2002-2010 ................ 26
                                      Table 17:   Antivirals Market, Top Five Countries of Europe, Revenue Forecasts ($m), 2010-2017 26
                                      Table 18:   Antivirals Market, Top Five Countries of Europe, Annual Cost of Therapy ($), 2002-2010
                                                  ....................................................................................................................................... 27
                                      Table 19:   Antivirals Market, Top Five Countries of Europe, Annual Cost of Therapy ($), 2010-2017
                                                  ....................................................................................................................................... 27
                                      Table 20:   Antivirals Market, Top Five Countries of Europe, Treatment Usage Patterns (Millions),
                                                  2002-2010 ...................................................................................................................... 28
                                      Table 21:   Antivirals Market, Top Five Countries of Europe, Treatment Usage Patterns (Millions),
                                                  2010-2017 ...................................................................................................................... 29
                                      Table 22:   Antivirals Market, Japan, Revenue ($m), 2002-2010 ..................................................... 30
                                      Table 23:   Antivirals Market, Japan, Revenue Forecasts ($m), 2010-2017 .................................... 30
                                      Table 24:   Antivirals Market, Japan, Annual Cost of Therapy ($), 2002-2010 ................................. 31
                                      Table 25:   Antivirals Market, Japan, Annual Cost of Therapy ($), 2010-2017 ................................. 31
                                      Table 26:   Antivirals Market, Japan, Treatment Usage Patterns (Millions), 2002-2010 ................... 32
                                      Table 27:   Antivirals Market, Japan, Treatment Usage Patterns (Millions), 2010-2017 ................... 33
                                      Table 28:   HIV/AIDS Therapeutics Market, Global, Revenue ($m), 2002–2010 ............................. 36
                                      Table 29:   HIV/AIDS Therapeutics Market, Global, Revenue Forecasts ($m), 2010–2017 ............. 36
                                      Table 30:   HIV/AIDS Therapeutics Market, Global, Geographical Distribution of Revenue ($m),
                                                  2002–2010 ..................................................................................................................... 39
                                      Table 31:   HIV/AIDS Therapeutics Market, Global, Geographical Distribution of Revenue ($m),
                                                  2010–2017 ..................................................................................................................... 40
                                      Table 32:   HIV/AIDS Therapeutics Market, Global, Annual Cost of Therapy ($), 2002–2010 ......... 41
                                      Table 33:   HIV/AIDS Therapeutics Market, Global, Annual Cost of Therapy ($), 2010–2017 ......... 41
                                      Table 34:   HIV/AIDS Therapeutics Market, Global, Treatment Usage Patterns (‘000), 2002–2010 43
                                      Table 35:   HIV/AIDS Therapeutics Market, Global, Treatment Usage Patterns (‘000), 2010–2017 43
                                      Table 36:   HIV/AIDS Therapeutics Market, Global, Key Drugs Going Off Patent, 2010–2017........ 51
                                      Table 37:   Hepatitis Therapeutics Market, Global, Revenue ($m), 2002–2010 ............................... 55
                                      Table 38:   Hepatitis Therapeutics Market, Global, Revenue Forecasts ($m), 2010–2017 .............. 55
                                      Table 39:   Hepatitis Therapeutics Market, Global, Revenue by Geography ($m), 2002–2010 ....... 58
                                      Table 40:   Hepatitis Therapeutics Market, Global, Revenue Forecasts by Geography ($m), 2010–
                                                  2017 ............................................................................................................................... 59
                                      Table 41:   Hepatitis Therapeutics Market, Global, Annual Cost of Therapy ($), 2002–2010 .......... 60
                                      Table 42:   Hepatitis Therapeutics Market, Global, Annual Cost of Therapy ($), 2010–2017 .......... 60
                                      Table 43:   Hepatitis Therapeutics Market, Global, Treatment Usage Pattern (‘000s), 2002–2010 . 61
                                      Table 44:   Hepatitis Therapeutics Market, Global, Treatment Usage Pattern (‘000s), 2010–2017 . 62
                                      Table 45:   Herpes Therapeutics Market, Global, Revenue ($bn), 2002–2010 ................................ 67
                                      Table 46:   Herpes Therapeutics Market, Global, Revenue Forecasts ($bn), 2010–2017 ............... 67
                                      Table 47:   Herpes Therapeutics Market, Global, Revenue by Geography ($m), 2002–2010 .......... 69
                                      Table 48:   Herpes Therapeutics Market, Global, Revenue Forecasts by Geography ($m), 2010–
                                                  2017 ............................................................................................................................... 70
                                      Table 49:   Herpes Market, Global, Annual Cost of Therapy ($), 2002–2010................................... 71
                                      Table 50:   Herpes Market, Global, Annual Cost of Therapy ($), 2010-2017 ................................... 71
                                      Table 51:   Herpes Market, Global, Treatment Usage Patterns (Millions), 2002–2010 .................... 72
                                      Table 52:   Herpes Market, Global, Treatment Usage Patterns (Millions), 2010–2017 .................... 72
                                      Table 53:   Influenza Therapeutics Market, Global, Revenue ($bn), 2002–2010 ............................. 78

Antivirals Market to 2017 - Increased Uptake of High Priced                                                               GBIHC163MR /Published APR 2012
Combination Drugs will Offset the Impact of Generics in the HIV                                                                                         Page 7
Therapeutics Market                                                                  © GBI Research. This report is a licensed product and is not to be copied,
                                                                                                                     reproduced, shared or resold in any form
                                      Table 54: Influenza Therapeutics Market, Global, Revenue Forecasts ($bn), 2010–2017 ............ 78
                                      Table 55: Influenza Therapeutics Market, Global Revenue by Country ($m), 2002–2010 ............. 79
                                      Table 56: Influenza Therapeutics Market, Global Revenue Forecasts by Country ($m), 2010–2017
                                                 .....................................................................................................................................
								
To top